Report 12-week data from the ALT-801 Phase 1 study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“anticipates a data read-out from the 6-week MAD study in Q2 2021, followed by 12-week data in Q3 2021.”
What we found
Evidence strength A What the grades mean
Filings say the company announced completion of the 12-week Phase 1 trial in September 2021 and reported positive topline 12-week data in Q3 2021, within the deadline.
-
A Altimmune, Inc. 8-K filed 2021-11-09
“The third quarter was a momentous time for our pemvidutide (ALT-801) program, as we delivered on positive topline data for the 12-week Phase 1 trial” ✓ confirmed on the page
-
A Altimmune, Inc. 8-K filed 2021-11-09
“Announced weight loss data from 12-week Phase 1 clinical trial of pemvidutide in overweight and obese subjects” ✓ confirmed on the page
-
A Altimmune, Inc. 10-K filed 2022-03-15
“In September 2021, we announced the completion of a 12-week Phase 1 clinical trial of pemvidutide in Australia under a clinical trial application.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- ALT-801 12-week Phase 1 data
- Target
- 12 weeks
- Where
- Australia
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Altimmune, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALT-024617 · Corrections policy